Skip to main content
. Author manuscript; available in PMC: 2010 Feb 2.
Published in final edited form as: J Immunol. 2008 Dec 1;181(11):7759. doi: 10.4049/jimmunol.181.11.7759

Table III.

Comparison of antigen-specific proliferation using fresh and cryopreserved pre-challenge PBMC

Animala Proliferation (mean CPM +/− 1 SD) against the following antigens:b
MSP1a F2-5 MSP2 P1 MSP1a F2-5 MSP2 P1
Immunized  Fresh PBMC Cryopreserved PBMC
3982 39,752 +/− 3,352 Negc 48,564 +/− 5,784 715 +/− 790
3937 13,802 +/− 2,021 2,522 +/− 1,472 27,744 +/− 6,736 442 +/− 395
3943 43,608 +/− 8,025 Neg 57,972 +/− 6,898 Neg
3959 39,360 +/− 1,828 761 +/− 223 44,298 +/− 6,426 733+/− 755
Controls  Fresh PBMC Cryopreserved PBMC
3962 Neg Neg 114 +/− 61 10 +/− 13
3989 Neg Neg 194 +/− 156 367 +/− 766
3960 Neg Neg 83 +/− 49 778 +/− 1,084
3991 744 +/− 1,555 1,223 +/− 2,231 198 +/− 259 16 +/− 82
a

PBMC were obtained on day 144 post immunization from vaccinates or controls and were tested immediately in a proliferation assay or cryopreserved in liquid nitrogen until they were tested approximately 17 months later.

b

Peptides were used at a final concentration of 10 μg/ml. Results are presented as the mean CPM +/− 1 SD of triplicate samples after subtracting the background response to medium. Responses significantly greater than the negative control MSP2 P1 peptide are in bold.

c

Neg indicates the responses was < 0 after subtracting the medium control.